| Drug ID: | Drug42 |
|---|---|
| Drug Name: | Prednisone |
| CID: | 5865 |
| DrugBank ID: | DB00635 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT02521064, , NCT01981889, , NCT02910245, , NCT02921555, , NCT04882683, , NCT05867329 |
| Molecular Formula: | C21H26O5 |
| Molecular Weight: | 358.4 g/mol |
| Isomeric SMILES: | C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C |
| Synonyms: | prednisone; 53-03-2; Dehydrocortisone; Supercortil; Metacortandracin; 1,2-Dehydrocortisone; Dacortin; Encorton; Paracort; Ancortone |
| Phase 0: | 16 |
| Phase 1: | 289 |
| Phase 2: | 880 |
| Phase 3: | 529 |
| Phase 4: | 214 |
| Description: | A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt383 | 5865 | Prednisone | 494514 | TYMSOS | Homo sapiens (human) | None | |
| dt384 | 5865 | Prednisone | 2625 | GATA3 | Homo sapiens (human) | None | |
| dt385 | 5865 | Prednisone | 5243 | ABCB1 | Homo sapiens (human) | None | |
| dt386 | 5865 | Prednisone | 100422871 | MIR3117 | Homo sapiens (human) | None | |
| dt387 | 5865 | Prednisone | 2 | A2M | Homo sapiens (human) | 11304663 | Prednisone results in decreased expression of A2M protein |
| dt388 | 5865 | Prednisone | 5243 | ABCB1 | Homo sapiens (human) | 22464980 | Valspodar inhibits the reaction [ABCB1 protein results in increased secretion of prednisone]|elacridar inhibits the reaction [ABCB1 protein results in increased secretion of prednisone]|abcb1 protein results in increased secretion of prednisone |
| dt389 | 5865 | Prednisone | 18671 | Abcb1a | Mus musculus (house mouse) | 15502009 | ABCB1A protein affects the susceptibility to prednisone |
| dt390 | 5865 | Prednisone | 18669 | Abcb1b | Mus musculus (house mouse) | 15502009 | ABCB1B protein affects the susceptibility to prednisone |
| dt391 | 5865 | Prednisone | 8714 | ABCC3 | Homo sapiens (human) | 15979871 | Prednisone results in increased activity of ABCC3 protein|prednisone promotes the reaction [ABCC3 protein affects the transport of calcein AM] |
| dt392 | 5865 | Prednisone | 9370 | ADIPOQ | Homo sapiens (human) | 29782964 | [prednisone co-treated with rosiglitazone co-treated with 1-methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT04882683 | Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis | None | UNKNOWN | Shandong Qilu Stem Cells Engineering Co., Ltd. | Ulcerative Colitis | DRUG: Prednisone|DRUG: Azathioprine|DRUG: Adalimu… | Details |
| NCT01981889 | Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease | PHASE4 | COMPLETED | University of British Columbia | Inflammatory Bowel Disease 11 | DRUG: Prednisone | Details |
| NL-OMON32200 | The pitfall of active inflammation during surveillance colonoscopy in inflammatory bowel disease patients - The influence of inflammation on surveillance colonoscopy | Not Available | Recruiting | Erasmus MC, Universitair Medisch Centrum Rotterdam | colitis inflammatory bowel disease (IBD);1001796… | Patients will be randomized to either two weeks d… | Details |
| NCT02910245 | Mercaptopurine Therapy in Ulcerative Colitis | PHASE3 | UNKNOWN | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Colitis, Ulcerative | DRUG: Mercaptopurine (Purinethol)|DRUG: Placebo|D… | Details |
| NCT03804931 | Fecal Microbiota Transplantation for Ulcerative Colitis | PHASE2|PHASE3 | RECRUITING | Guangzhou First People's Hospital | Ulcerative Colitis|Fecal Microbiota Transplantati… | PROCEDURE: Fecal microbiota transplantation|PROCE… | Details |
| NCT05867329 | A Trial for Acute Severe Ulcerative Colitis | PHASE4 | RECRUITING | Berinstein, Jeffrey | Ulcerative Colitis Acute | DRUG: Cyclosporine Injection (IV)|DRUG: Cyclospor… | Details |
| NCT02921555 | Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis | PHASE4 | TERMINATED | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa | Ulcerative Colitis | DRUG: Methylprednisolone|DRUG: Prednisone | Details |
| NCT02521064 | Effects of Exclusive Enteral Nutrition on the Microbiome in Pediatric Inflammatory Bowel Disease | None | COMPLETED | McMaster Children's Hospital | Inflammatory Bowel Diseases | DIETARY_SUPPLEMENT: Exclusive Enteral Nutrition (… | Details |
| NCT04624230 | Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | PHASE3 | RECRUITING | Pfizer | Ulcerative Colitis | DRUG: tofacitinib | Details |
| NCT06651281 | Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) | PHASE3 | RECRUITING | Merck Sharp & Dohme LLC | Crohn Disease|Colitis, Ulcerative | DRUG: Tulisokibart|DRUG: Placebo to tulisokibart | Details |
| NCT04857112 | Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis | PHASE2 | ACTIVE_NOT_RECRUITING | Bausch Health Americas, Inc. | Ulcerative Colitis | DRUG: Low Dose MT-1303|DRUG: High Dose MT-1303|DR… | Details |
| NCT05986136 | Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease | PHASE2|PHASE3 | RECRUITING | Mostafa Bahaa | Inflammatory Bowel Diseases | DRUG: Mesalamine|DRUG: Dapagliflozin 10mg Tab | Details |
| NCT06353828 | Phase 2a Study to Evaluate IcBD-01 Enema in Active Ulcerative Colitis Patients | PHASE2 | ACTIVE_NOT_RECRUITING | CannaMore Biotechs | Ulcerative Colitis | DRUG: CBD, synthetic form|DRUG: Placebo | Details |
| NCT04478825 | Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis | PHASE1 | TERMINATED | Bridge Biotherapeutics, Inc. | Ulcerative Colitis | DRUG: BBT-401-1S | Details |
| NCT06570772 | Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio | PHASE3 | RECRUITING | Alvotech Swiss AG | Ulcerative Colitis | BIOLOGICAL: AVT16|BIOLOGICAL: Vedolizumab | Details |
| NCT01290042 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181. | PHASE1 | COMPLETED | Amgen | Ulcerative Colitis|Crohn's Disease | DRUG: AMG 181|OTHER: Placebo for AMG 181 | Details |
| NCT05507203 | ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 | PHASE3 | RECRUITING | Abivax S.A. | Ulcerative Colitis | DRUG: ABX464|DRUG: Placebo | Details |
| NCT00207688 | A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients | None | COMPLETED | Janssen Research & Development, LLC | Ulcerative Colitis | DRUG: Infliximab 5 mg/kg|DRUG: Infliximab 10 mg/k… | Details |
| NCT04677179 | A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) | PHASE2 | TERMINATED | Nektar Therapeutics | Colitis, Ulcerative | DRUG: LY3471851|DRUG: Placebo | Details |
| NCT02611830 | Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis | PHASE3 | COMPLETED | Takeda | Colitis, Ulcerative | DRUG: Vedolizumab 300 mg IV|DRUG: Placebo IV|DRUG… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| S04 | T-cell homing and retention | T-cell trafficking | vedolizumab; anti-MAdCAM1 antibodies ; etrolizumab | Inhibition of the interaction between α4β7 integrins on T c… | Details |
| S06 | Anti-fibrosis | fibrosis; tissue remodelling | GS-5745; STNM01 | Tissue remodelling and destruction in patients with IBD is … | Details |
| S07 | Blockade of cytokine | Cytokine signalling | apremilast; roflumilast; filgotinib; tofacitinib; ABT494; ABT-874; ustekinumab; isankizumab; LY-2525623; AMG139; MEDI2079; guselkumab | Various T-cell subsets, their differentiation pathways and … | Details |
Nodular Pachymeningitis Associated With Relapsing Polychondritis and Crohn Dise…
PMID: 34078656
Year: 2021
Relationship Type:
Treatment
Score: 6.5
OBJECTIVES: To review the previous literature on the associations of pachymeningitis with Crohn disease (CD) and relapsing polychondritis (RP) and to…
Favorable outcome of COVID-19 in a young woman with severe Crohn's disease on r…
PMID: 33331521
Year: 2020
Relationship Type:
Association
Score: 6.5
COVID-19 is a viral disease caused by SARS-CoV-2 that compromises the host immune response in severe cases, promoting a hyperinflammation that result…
Electrochemiluminescence immunoassay method underestimates cortisol suppression…
PMID: 25152591
Year: 2014
Relationship Type:
Treatment
Score: 6.3
AIM: To evaluate cortisolemia by using conventional electrochemiluminescence immunoassay (ECLIA) method compared to liquid chromatography-tandem mass…
Pulmonary cryptococcosis in a patient with Crohn's disease treated with prednis…
PMID: 22647638
Year: 2013
Relationship Type:
Treatment
Score: 6.1
BACKGROUND: Biotherapies targeting TNFalpha were proven to be effective in the most severe cases of Crohn's Disease, a chronic granulomatous inflamma…